This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Four months ago, a small pharmaceuticalscompany bought a medicine used to combat a rare growth disorder in children and quickly raised the list price by 150%. But the company, Eton Pharmaceuticals, argues there is no other way to keep its treatment on the market and make a profit.
WASHINGTON — Most executives at pharmaceuticalcompanies haven’t directly donated to political candidates over the final stretch of the 2024 campaign. 30, five gave to Democratic candidates, even though Democratic lawmakers passed the most aggressive drugpricing reform in decades in 2022.
The biggest enticement that large pharmacy benefit managers offer to the employers that hire them is drug rebates — a steady stream of money sent back to their clients, a tangible symbol of the discounts that PBMs are able to wrangle out of pharmaceuticalcompanies. Continue to STAT+ to read the full story…
Organisation of Pharmaceutical Producers of India (OPPI) in partnership with BCG has released a new report, titled “Winning in Indian Healthcare”. Global pharmaceuticalcompanies have played a pivotal role in transforming the healthcare sector in India.
As Election Day 2024 gets closer, STAT’s First Opinion asked executives from leading biotech and pharmaceuticalcompanies to reflect on how their industry is being portrayed in the presidential campaign — and what their hopes are for a new presidential administration. You
The Indian pharmaceuticals market (IPM) is projected to grow by 8 per cent year-on-year in FY26, supported by a 4 per cent-5 per cent increase in drugprices, volume growth, and new product launches. Most large pharmaceuticalcompanies rated by Ind-Ra fall into high investment-grade categories.
And contrary to what you might read, drug spending growth was *not* driven by purportedly “skyrocketing” drugprices. In reality, nearly all drug spending growth occurred due to growth in the number of people treated, prescriptions dispensed, and other nonprice factors. healthcare expenditures. healthcare expenditures.
Structuring patient assistance programs as independent non-profit foundations helps pharmaceuticalcompanies reduce regulatory and legal exposure while allowing for more holistic, patient-centered support. Lastly, PAPs that are directly managed by pharmaceuticalcompanies may also struggle with public image issues.
In one of the fierier remarks from the roundtable, RFK Jr said: “At every level, doctors, other providers, our hospitals, the pharmaceuticalcompanies, the insurance companies, all make money by keeping us sick. We need to fundamentally change that so that we are focusing on curing disease and making people better.”
This could evolve into pharmaceuticalcompanies dealing with semi-permanent higher input costs and other interlinked challenges for longer than current baseline predictions. The magnitude of the hindrance to sales growth and profitability will impact companies from multiple different angles. Free Report.
AI in value-based pricing and RWE generation AI has the potential to transform value-based pricing (VBP) by leveraging machine learning for dynamic pricing models that adjust drugprices based on real-world patient outcomes.
This could evolve into pharmaceuticalcompanies dealing with semi-permanent higher input costs and other interlinked challenges for longer than current baseline predictions. The magnitude of the hindrance to sales growth and profitability will impact companies from multiple different angles. Free Report.
The industry is awaiting guidance on a rebate approach to the contentious drug discount program for hospitals and aiming for tighter oversight. The 340B DrugPricing Program has long been a contentious issue for pharma. Please let us know if you have feedback.
This quiz competition is brought to you by Pharma Industry Townhall – Sales & Marketing scheduled for 16th March 2024 at Radisson Blue, Marol, Andheri East, Mumbai. a) Medical Research b) Marketing Representative c) Medication Review d) Market Regulation MR' commonly refers to Marketing Representative in pharmaceutical marketing.
accelerates its crackdown on drugpricing through new legislation and regulatory enforcement, pharma companies in China, India, Japan, and South Korea are feeling the ripple effect. This article explores whats behind the sudden slump in Asian pharmaceutical equities and why U.S. As the U.S. Table of Contents The U.S.
… Four months ago, a small pharmaceuticalscompany bought a medicine used to combat a rare growth disorder in children and quickly raised the list price by 150% , STAT says. European pharmaceutical bosses have called on the European Union to increase drugprices toward the much higher levels paid by the U.S.,
WASHINGTON — Pharmaceuticalcompanies’ efforts to scuttle President Biden’s signature health care achievement, empowering Medicare to negotiate prescription drugprices, will soon face their first big tests. Continue to STAT+ to read the full story…
Editors picks George Frey/Reuters Deep Dive A decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology Over the past 10 years, PD1-blocking medicines have transformed cancer care. 4, 2024 Permission granted by Bristol Myers Squibb Deep Dive // Brain drug revival Psychiatry drugs finally have pharma’s attention.
How Recent Executive Orders Impact the DrugPricing Landscape Nicholas Saraceno, Editor May 30th 2025 Podcast Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drugpricing and market access.
It’s an understatement to say there’s a lot going on right now that could impact pharmaceuticalcompanies’ and drug brands’ patient access strategies. With pricing, Medicare frameworks, pharmacy benefit manager rebates, and more seemingly up for redesign, it would be hard not to fixate on regulatory uncertainty.
Role of HEOR in Pharmaceutical Industry With budget constraints tightening and drugprices facing greater scrutiny, Health Economics and Outcomes Research has become a cornerstone of modern pharmaceutical strategy. How Does the HEOR Model Work for PharmaceuticalCompanies?
Advertisements eviscerating and glorifying pharmacy benefit managers have been around for years, but have intensified over the past three months as Congress scrutinizes the role these middlemen play in shaping high prescription drugprices , STAT tells us. The company hopes to launch the product in the U.S. in 2024.
Sandoz has faced and may in the future face strong competition from other generic and biosimilar pharmaceuticalcompanies, which aggressively compete for market share, including through significant price competition. The company had revenues of $9.6bn both in 2020 and last year. The site employs around 250 people.
Over the past couple years, the demand for this RSV vaccine has continued to be high; in fact, Sanofi had announced in October 2023 that the extraordinary demand had caused shortages impacting the 2023-2024 season. February 2, 2024. 2 The CDC did not revise any recommendations for the 50 mg doses at that time. June 9, 2025.
” The remarks reiterate concerns raised by health policy and law experts that partnerships between pharma and telehealth companies could increase prescribing of unnecessary and expensive medications. But of the six executives who donated to individual candidates between July 1 and Sept.
that is distrustful of institutions and eager to blame large corporations, including major pharmaceuticalcompanies, for Americans’ poor health. Kennedy Jr. Insurers could be squeezed if Democrat-passed subsidies to Affordable Care Act plans expire, driving people out of the market.
By Ned Pagliarulo • June 4, 2025 George Frey/Reuters Deep Dive A decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology Over the past 10 years, PD1-blocking medicines have transformed cancer care. You can unsubscribe at anytime. By Jonathan Gardner • Sept. By Jonathan Gardner • Sept. TechTarget, Inc.s
Compounded GLP-1RAs have completely disrupted pricing frameworks for Wegovy and Mounjaro, what happens now? Robert Barrie June 27, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The list price for a month’s supply of 2.4mg Wegovy – the drug’s highest does – is $1,350 in the US, whereas the same dose in the UK costs £175.80
And though Roche and Bristol Myers acquired both their medicines in high-priced acquisitions, they haven’t yielded significant sales: Rozlytrek generated about 134 million Swiss francs in 2024 , while Augtyro pulled in just $38 million. Informa PLCs registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales.
Go deeper with GlobalData Reports United States of America (USA) DrugPricing and Reimbursement Lands. He noted that these conflicts of interest continue to the current day, with ACIP members receiving substantial funding from pharmaceuticalcompanies. Data Insights The gold standard of business intelligence.
More specifically, the Indian Pharmaceutical Alliance, an organisation representing the country’s largest pharmaceuticalcompanies, has urged the government to reduce import tariffs from the current 10% to zero for pharmaceutical imports from the US.
The Trump Administration has revived the most-favored nation (MFN) drugpricing model as a seven-year test, which would tie US drugprices to the lowest prices paid by certain OECD countries—an approach previously blocked by courts. Concerns over price controls. What is MFN model pricing? China wins?
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content